Epidemiology and End Results, the incidence of ENKTL in the United
States has increased in the past few years with an estimated relative change of up to 10% per year, 6 and higher rate in Hispanics than blacks, non-Hispanic whites and Native Americans. 7 ENKTL frequently involves nasal cavity, nasopharynx and occasionally occurs primarily in nonnasal areas, including the skin, gastrointestinal tract, lung, liver, salivary gland, and testis. 8 The median age of ENKTL patients at diagnosis is around 50-55 years old. Most patients presents with early stage. The 5-year overall survival rate is between 40% and 50%. 7, 8 Histopathologically 
10-14
The clinical features and outcome of ENKTL patient in Taiwan has not been reported. We aimed to describe the general features of ENKTL in Taiwan and to review in detail previous landmark publications.
| ME THODS AND MATERIAL S

| Patients selection
Clinical data were retrieved from medical records of adult patients 
| Treatment
According to our institutional guidelines, patients with early-stage disease were treated with short-course chemotherapy and involvedfield radiotherapy. Patients with advanced stage disease were treated with intensive chemotherapy followed by consolidative stem cell transplantation in fit responders. CHOP or CHOP-like regimens as frontline therapy were employed at our center. 
| RE SULTS
| Patient characteristics
A total of 101 patients fit the diagnostic criteria for ENKTL (Table 1) . 
| Immunohistochemical stain
Results of immunohistochemical stain are listed in Figure 1A ). For treatment responder and nonresponder, the median EBV-DNA viral loads were 218 vs 91 050 copies/mL (P = 0.226, Figure 1B ). An optimal cutoff value of statistically significance compared to patients without hemophagocytosis/HLH at relapse (P = 0.174, Figure 2C ).
| Treatment modalities and responses
Most patients with stage I/II disease received sandwiched combination of chemotherapy and RT (N = 61, 79.2%). The treatment modalities and responses of ENKTL patients are summarized in Table 2 .
CHOP was given in 54 (88.5%) patients, 6 (9.8%) patients received COP regimen, and CVOP (cyclophosphamide, etoposide, vincristine, prednisone) in one (1.6%) case. Fourteen patients received chemotherapy alone with CHOP (n = 8, 57.2%), COP (n = 5, 35.7%) or CVOP (n = 1, 7.1%). Two (2.6%) patients received local RT without systemic chemotherapy. The numbers of stage I/II patients who achieved CR, PR, and PD after therapy were 57 (74%), six (7.8%), and two (2.6%), respectively. Twelve patients lost follow-up or died and treatment response was not evaluable. Sixteen patients (28.6%) relapsed after achieving CR, with median DFS of 6.2 months.
TA B L E 1 Patients and disease characteristics (N = 101)
Characteristics n (%) 
| Hematopoietic stem cell transplantation (HSCT)
Seven patients underwent HSCT, including five with autologous and two with allogeneic HSCT (Table 2) . One patient underwent HSCT as consolidative treatment after first CR, one patient after initial PR, four patients as part of salvage treatment after disease relapsed, and one patient as salvage treatment with disease refractory status. One patient with stage II disease underwent autologous HSCT at PR status died of transplantation-related mortality. One patient with stage IV disease received allogeneic HSCT as salvage therapy died of relapsed disease.
Totally, five patients, one underwent autologous transplantation in first CR, and the other four patients received HSCT after second CR (3 autologous, 1 allogeneic), were alive and in durable remission of 44-82 months. 
| Survival analysis
| Multivariate analysis
Multivariate analysis identified that age ≥ 60 (HR 2.417, 95% CI 
| D ISCUSS I ON
According to previous studies from Hong Kong, China, Korea, and Japan have been reported, [1] [2] [3] 18, 19 ENKTL has a higher incidence in East Asia. Moreover, in US populations, ENKTL is also more prevalent 
OS. The international study conducted by Kim and colleagues also
showed that a detectable EBV-DNA titer was an independent prognostic factor, but the impact of quantitative PCR was not assessed because the method was not validated in the study. 22 In this cohort, combination of anthracycline-containing chemotherapy and RT in Ann Arbor stage I/II patients showed a good initial overall response rate (ORR) and CR rate. However, the relapse rate was high (29.3%) with median DFS of 6.2 months. In the early 2000s, patients with ENKTL were traditionally treated with anthracyclinecontaining chemotherapies, but the reported outcomes of CHOP or CHOP-like chemotherapy alone were poor. 1 The reported 5-year OS rates for patients with localized nasal ENKTL treated with CHOP followed by involved-field RT are less than 50%. 18, 30 ENKTL cells express the multidrug resistance (MDR)1/ABCB1 gene and its product, P-glycoprotein, which acts as an efflux pump of various drugs including doxorubicin and vincristine. 31 The MDR phenomenon is believed to be the major reason why ENKTL is resistant to CHOP-like chemotherapies that consist mainly of MDR-related agents. This led to the development of novel therapeutic strategies with upfront RT with or without non-MDR-related chemotherapy. In the Korean Consortium for Improving Survival of Lymphoma Study Group, cisplatin was selected for concurrent chemoradiotherapy as a radiation sensitizer, followed by three courses of VIPD (etoposide, ifosfamide, cisplatin, and dexamethasone), which resulted in a better response rate, PFS and OS, and a lower relapse rate. 32 In the Japan Clinical Oncology Group JCOG0211 Study, 27 patients were treated with concurrent were conducted in China. Concurrent chemoradiotherapy with cisplatin followed by two courses VIDL (etoposide, ifosfamide, dexamethasone, L-asparaginase) was reported from Korea. 36 Fiveyear OS rate up to 85% with median follow-up of 63 months was reported from the trial of GELOX regimen. A high relapse rate of 30%, mostly early distant relapse, was reported in the VIDL trial.
The author commented that disease relapse outside the radiation target volume might be associated with microscopic metastasis at the time of diagnosis. The results of all relevant studies are listed in Table 4 . However, long-term relapse rate, DFS, PFS or OS were not consistently available in all studies. The long-term outcome of stage I/II ENKTL patients treated with CHOP-based chemoradiotherapy in this study seemed to be better than patients in previously reported studies, 18, 30 and was not inferior to some results of combined chemoradiotherapy with non-MDR-related regimens. 12, 13, 33, 34, 36 We considered the better results of CHOP-based chemoradiotherapy in this study comparing to previously reported cohorts might be due to the heterogeneity of ENKTL itself. However, combined chemoradiotherapy with CHOP is not the optimal treatment for ENKTL due to the high relapse rate. As a retrospective study, there are inherent limitations of this analysis to make conclusion. Due to the rarity of the disease and the difficulty of conducting randomized controlled trials, the optimal treatment regimen has not been determined.
In this study, an extremely low response rate and dismal outcome were observed in stage III/IV ENKTL patients treated with CHOP/ relapsed NK/T-cell lymphoma failing L-asparaginase regimens and two patients relapsed after allogeneic HSCT were treated with the anti-PD1 antibody pembrolizumab. 43 The ORR was 100% after a median of 7 cycles of pembrolizumab. Five patients achieved sustained CR after a median follow-up time of 6 (2-10) months. Further studies are warranted to evaluate and confirm the efficacy of anti-PD1
antibody. The treatment approach to ENKTL has evolved over the past two decades. However, a recent retrospective study from Japan reported the limitations of the new therapeutic strategies and novel regimens, in particular that almost no improvement in early disease progression and 1-year PFS, as well as approximately 20% of patients died or experienced disease relapse. 10 There is no consensus about the best consolidative therapy.
Autologous HSCT as a consolidation therapy for ENKTL at first CR was examined in a retrospective study of 62 patients (advanced stage, N = 31). 44 With a median follow-up of 43.3 months, the 3-year OS and PFS were 67.6% and 64.5% in early-stage patients and 52.3% and 40.1% for advanced stage patients. There were 
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